You-Jung Yang1, Sung-Jig Lim2, Jeong-Yoon Song3. 1. Department of Nuclear Medicine, Medical College of Kyung Hee University, 149 Sang-Il-dong, Kangdong-gu, Seoul, 134-727 South Korea. 2. Department of Pathology, Medical College of Kyung Hee University, Seoul, Korea. 3. Department of Surgery, Medical College of Kyung Hee University, Seoul, Korea.
Abstract
PURPOSE: To evaluate the potential of Tc-99m diphosphonate as a tracer for sentinel lymph node biopsy in breast cancer. METHODS: Lymphoscintigraphs of 35 patients (50.9 ± 10.2 years) with breast cancer were acquired after administering a subareolar intradermal injection of Tc-99m diphosphonate 18 h before surgery. Static images were taken within 15 min (early phase) and 15 h after injection (delayed phase). The lymphoscintigraphic identification rate was defined as the percentage of subjects studied with visible foci at axillae. Sentinel lymph node biopsies were performed using a gamma probe and by blue dye injection. Any node that was radioactive or stained with blue dye was labeled as a sentinel lymph node. Lymph nodes without radioactivity or blue dye staining were defined as non-sentinel lymph nodes. The intraoperative identification rate was defined as the percentage of patients with a radioactive sentinel lymph node. Percentages of lymphoid cells expressing S-100, CD83, and CD1a were compared. RESULTS: The lymphoscintigraphic identification rate was 94.3% (33/35) during the early phase and 96.9% (31/32) during the delayed phase, whereas the intraoperative identification rate was 94.3% (33/35). The mean percentages of lymphoid cells that stained positively for S-100 or CD83 were lower in sentinel lymph nodes than in non-sentinel lymph nodes (1.5% vs. 9.0% for S-100, and 4.5% vs. 9.3% for CD83, respectively, p = 0.0286). The mean percentages of lymphoid cells in sentinel lymph nodes and non- sentinel lymph nodes expressing CD1a were 3.3% and 7.0%, respectively (p = ns). CONCLUSIONS: Tc-99m diphosphonate can reliably detect regional lymph nodes in breast cancer.
PURPOSE: To evaluate the potential of Tc-99m diphosphonate as a tracer for sentinel lymph node biopsy in breast cancer. METHODS: Lymphoscintigraphs of 35 patients (50.9 ± 10.2 years) with breast cancer were acquired after administering a subareolar intradermal injection of Tc-99m diphosphonate 18 h before surgery. Static images were taken within 15 min (early phase) and 15 h after injection (delayed phase). The lymphoscintigraphic identification rate was defined as the percentage of subjects studied with visible foci at axillae. Sentinel lymph node biopsies were performed using a gamma probe and by blue dye injection. Any node that was radioactive or stained with blue dye was labeled as a sentinel lymph node. Lymph nodes without radioactivity or blue dye staining were defined as non-sentinel lymph nodes. The intraoperative identification rate was defined as the percentage of patients with a radioactive sentinel lymph node. Percentages of lymphoid cells expressing S-100, CD83, and CD1a were compared. RESULTS: The lymphoscintigraphic identification rate was 94.3% (33/35) during the early phase and 96.9% (31/32) during the delayed phase, whereas the intraoperative identification rate was 94.3% (33/35). The mean percentages of lymphoid cells that stained positively for S-100 or CD83 were lower in sentinel lymph nodes than in non-sentinel lymph nodes (1.5% vs. 9.0% for S-100, and 4.5% vs. 9.3% for CD83, respectively, p = 0.0286). The mean percentages of lymphoid cells in sentinel lymph nodes and non- sentinel lymph nodes expressing CD1a were 3.3% and 7.0%, respectively (p = ns). CONCLUSIONS:Tc-99m diphosphonate can reliably detect regional lymph nodes in breast cancer.
Entities:
Keywords:
Breast cancer; Sentinel node; Tc-99m diphosphonate
Authors: Alistair J Cochran; Rong-Rong Huang; Jonathan Lee; Eijun Itakura; Stanley P L Leong; Richard Essner Journal: Nat Rev Immunol Date: 2006-09 Impact factor: 53.106
Authors: Rafael Botella-Estrada; Francisco Dasí; David Ramos; Eduardo Nagore; Maria Jose Herrero; Julia Giménez; Carlos Fuster; Onofre Sanmartín; Carlos Guillén; Salvador Aliño Journal: Melanoma Res Date: 2005-04 Impact factor: 3.599
Authors: B A Kapteijn; O E Nieweg; I Liem; W J Mooi; A J Balm; S H Muller; J L Peterse; R A Valdés Olmos; C A Hoefnagel; B B Kroon Journal: Ann Surg Oncol Date: 1997-03 Impact factor: 5.344
Authors: Rong Rong Huang; Duan-Ren Wen; Jin Guo; Armando E. Giuliano; Mai Nguyen; Regina Offodile; Stacey Stern; Roderick Turner; Alistair J. Cochran Journal: Breast J Date: 2000-07 Impact factor: 2.431
Authors: J J Albertini; G H Lyman; C Cox; T Yeatman; L Balducci; N Ku; S Shivers; C Berman; K Wells; D Rapaport; A Shons; J Horton; H Greenberg; S Nicosia; R Clark; A Cantor; D S Reintgen Journal: JAMA Date: 1996-12-11 Impact factor: 56.272
Authors: A J Cochran; D R Wen; Z Farzad; M A Stene; W McBride; A M Lana; D S Hoon; D L Morton Journal: Anticancer Res Date: 1989 Jul-Aug Impact factor: 2.480
Authors: R F Uren; R B Howman-Giles; J F Thompson; D Malouf; G Ramsey-Stewart; F W Niesche; S B Renwick Journal: J Nucl Med Date: 1995-10 Impact factor: 10.057